医学
糖尿病
疾病
生物信息学
炎症
遗传增强
发病机制
胰岛素抵抗
重症监护医学
免疫学
内科学
基因
内分泌学
遗传学
生物
作者
Mohadesse Dehghan,Fatemeh Ghorbani,Sajad Najafi,Neda Ravaei,Maede Karimian,Kambiz Kalhor,Abolfazl Movafagh,Seyed Mohsen Aghaei Zarch
标识
DOI:10.1016/j.diabres.2022.109945
摘要
Diabetes mellitus (DM) has been the most prevalent global metabolic disease, turning into a serious risk for human health. Several researches have recorded a role for inflammation and immunity in the pathogenesis of both in T1DM and in T2DM. Lots of chemical agents are available to control and to cure diabetic patients, which are not always sufficient for euglycemia maintenance and late stage diabetic complications avoidance. Therefore, newborn therapeutic methods to refine clinical outcomes in DM are required. Nucleic-acid-based therapy also known as gene expression level regulator within the target cells has been calculated to be promising in various diseases. Thus, pronounced attempts have been dedicated to develop new targeted molecular therapy aimed at improving insulin resistance in DM. This review mainly focuses on recent progress in DM molecular therapy and whether, has potential efficacy against inflammatory mediators involved in DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI